The National Comprehensive Cancer Network® (NCCN®) has released a free, on-demand webinar titled “Why Should I Consider a ...

The details of Dr. Reneau’s presentations are as follows ... dose and would have met the eligibility criteria for the ongoing registrational Phase 3 clinical trial based on ≥1 and ≤3 prior therapies, ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC –– Company expects to present data ...

The oral presentation from the LUCE-1 clinical trial in Usher 1B builds on the data presented at the FLORetina medical conference in December 2024 with updates from more patients dosed since then, and ...

The oral presentation from the LUCE-1 clinical trial in Usher 1B builds on the data presented at the FLORetina medical conference in December 2024 with updates from more patients dosed since then ...

today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference ...